van Asperen CJ - Search Results

1

TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.

Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van 't Veer LJ. Ruijs MW, et al. Among authors: van asperen cj, van der hout ah, van t veer lj. J Med Genet. 2010 Jun;47(6):421-8. doi: 10.1136/jmg.2009.073429. J Med Genet. 2010. PMID: 20522432 Free article.

2

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P. Oldenburg RA, et al. Among authors: van asperen cj. Cancer Res. 2003 Dec 1;63(23):8153-7. Cancer Res. 2003. PMID: 14678969

3

What's the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer.

van Dijk S, Otten W, Timmermans DR, van Asperen CJ, Meijers-Heijboer H, Tibben A, Breuning MH, Kievit J. van Dijk S, et al. Among authors: van asperen cj. Genet Med. 2005 Apr;7(4):239-45. doi: 10.1097/01.gim.0000159902.34833.26. Genet Med. 2005. PMID: 15834241 Free article.

4

Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van gool ar. Patient Educ Couns. 2007 Jan;65(1):58-68. doi: 10.1016/j.pec.2006.05.006. Epub 2006 Jul 26. Patient Educ Couns. 2007. PMID: 16872788

5

Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.

van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W. van Dijk S, et al. Among authors: van asperen cj. J Clin Oncol. 2006 Aug 1;24(22):3672-7. doi: 10.1200/JCO.2005.03.7259. J Clin Oncol. 2006. PMID: 16877736

6

A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Riedijk SR, van Dooren S, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van dooren s, van gool ar. Psychooncology. 2007 Apr;16(4):320-8. doi: 10.1002/pon.1062. Psychooncology. 2007. PMID: 16909428

7

Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van gool ar. Eur J Cancer. 2007 Jan;43(1):71-7. doi: 10.1016/j.ejca.2006.08.023. Epub 2006 Oct 11. Eur J Cancer. 2007. PMID: 17045473

8

The common sense model of self-regulation and psychological adjustment to predictive genetic testing: a prospective study.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A. van Oostrom I, et al. Among authors: van asperen cj, van gool ar. Psychooncology. 2007 Dec;16(12):1121-9. doi: 10.1002/pon.1178. Psychooncology. 2007. PMID: 17328098

9

Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort.

Jacobi CE, van Ierland Y, van Asperen CJ, Hallensleben E, Devilee P, Jan Fleuren G, Kenter GG. Jacobi CE, et al. Among authors: van asperen cj, van ierland y. Genet Med. 2007 Mar;9(3):173-9. doi: 10.1097/GIM.0b013e318032e4ab. Genet Med. 2007. PMID: 17413421 Free article. Clinical Trial.

10

The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life.

Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A. Vos J, et al. Psychooncology. 2008 Aug;17(8):822-30. doi: 10.1002/pon.1311. Psychooncology. 2008. PMID: 18157792

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

219 results

Search Page